News | Search | Subscribe | My Account | About Us | Contact Us | Repertoire Home
July 28, 2016

From The Journal of Healthcare Contracting

  • BJC Healthcare’s Stephen Kiewiet to speak at IDN Insights East in Atlanta, September 8-9
  • Manufacturer News

  • Eli Lilly CEO to retire
  • Teva to divest more than 75 generic drugs to settle competition concerns related to acquisition of Allergan’s generic business
  • Sanofi receives FDA approval for Adlyxin for treatment of adults with Type 2 diabetes
  • Sanofi Pasteur ships first of 2016-2017 seasonal influenza vaccine doses in U.S.
  • Provider Services News

  • Huron Consulting Group to acquire HSM Consulting
  • Hospital and IDN News

  • CMS announces first release of Overall Hospital Quality Star Rating on Hospital Compare
  • Hospitals are hit with 88% of all ransomware attacks
  • Stock Watch

  • Health Stocks
  • From The Journal of Healthcare Contracting
    BJC Healthcare’s Stephen Kiewiet to speak at IDN Insights East in Atlanta, September 8-9

    Stephen Kiewiet, VP supply chain operations for BJC Healthcare (CS), will speak at the IDN Insights East meeting, which will be held September 8-9, 2016 in Atlanta, Georgia. Kiewiet will speak on the “Working with, identifying decision makers, and selling to large customers” panel. During this panel attendees will hear from suppliers and providers regarding the do’s and don'ts in working with and selling to large customers, including ideas on how to best collaborate to reduce variation in all business practices.

    To register, visit www.eventbrite.com/e/idn-insights-east-showcasing-level-iv-healthcare-systems-tickets-22788872130.

    Questions? Contact Anna McCormick at amccormick@mdsi.org.

    -back to top-
    Manufacturer News
    Eli Lilly CEO to retire

    Eli Lilly & Co (Indianapolis, IN) announced that CEO John Lechleiter will retire by the end of 2016. Lechleiter has worked at Eli Lilly since 1979 and served as CEO since April 2008. He will be succeeded by Eli Lilly SVP David Ricks, effective January 1, 2017. Ricks has served since 2012 as president of Lilly Bio-Medicines, where he has overseen late-stage drug trials and global marketing. He has also held other leadership positions at Lilly.

    -back to top-
    Teva to divest more than 75 generic drugs to settle competition concerns related to acquisition of Allergan’s generic business

    Teva Pharmaceutical Industries Ltd (Petach Tikva, Israel) agreed to sell the rights and assets related to 79 pharmaceutical products to settle FTC charges that its proposed $40.5 billion acquisition of Allergan plc’s (Dublin, Ireland) generic pharmaceutical business would be anticompetitive. Teva will divest the drug portfolio to eleven firms. The acquirers of the divested products are Mayne Pharma Group Ltd, Impax Laboratories Inc, Dr. Reddy’s Laboratories Ltd, Sagent Pharmaceuticals Inc, Cipla Limited, Zydus Worldwide DMCC, Mikah Pharma LLC, Perrigo Pharma International D.A.C., Aurobindo Pharma USA Inc, Prasco LLC, and 3M Company. To read more, visit .

    -back to top-
    Sanofi receives FDA approval for Adlyxin for treatment of adults with Type 2 diabetes

    Sanofi (Paris, France) received FDA approval for Adlyxin (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with Type 2 diabetes. GLP-1 is a peptide hormone that is released within minutes after eating a meal. It is known to suppress glucagon secretion from pancreatic alpha cells and stimulate glucose-dependent insulin secretion by pancreatic beta cells. Adlyxin increases glucose-dependent insulin release, decreased glucagon secretion, and slows gastric emptying. Adlyxin will be available in a disposable pre-filled pen in a single dose of 20 micrograms. Patients will also receive a disposable pre-filled pen in a single dose of 10 micrograms that they should initiate once daily for 14 days. On day 15, patients will increase dosage to 20 micrograms once daily. For more information, visit http://mediaroom.sanofi.com/%E2%80%8Bsanofi-receives-fda-approval-of-adlyxintm-for-treatment-of-adults-with-type-2-diabetes/.

    -back to top-
    Sanofi Pasteur ships first of 2016-2017 seasonal influenza vaccine doses in U.S.

    Sanofi Pasteur (Swiftwater, PA) announced that its first doses of Fluzone (Influenza Vaccine) for the 2016-2017 influenza season have been released by the FDA for shipment. This is the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. healthcare providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs. The CDC recommends annual influenza vaccination for everyone six months of age and older, with rare exception, and recommends receiving the vaccine as soon as it is available to help with prevention even before the season begins.

    -back to top-
    Provider Services News
    Huron Consulting Group to acquire HSM Consulting

    Huron Consulting Group Inc (CS) entered into an agreement to acquire Healthcare Services Management Inc (HSM) (Quincy, MA), a firm specializing in healthcare IT and management consulting. HSM’s more than 100 consultants will join Huron and David Devine, HSM’s CEO, will join as a managing director. The acquisition will strengthen Huron’s ability to help healthcare providers implement and optimize technologies that harness data to improve the quality and cost of care and better manage patient populations. HSM will complement to Huron’s current IT and EHR consulting services, adding expertise in Cerner, MEDITECH, Allscripts, NextGen and other prevalent systems. Together, Huron and HSM expect to cover virtually the full range of EHR technology solutions. For reporting purposes, HSM will be included in the Huron Healthcare segment. Terms of the acquisition, which is expected to close in August 2016, were not disclosed.

    -back to top-
    Hospital and IDN News
    CMS announces first release of Overall Hospital Quality Star Rating on Hospital Compare

    The CMS released its Overall Hospital Quality Star Rating program. The ratings are a composite metric of one to five stars, with a five-star rating being the best. Currently, 102 hospitals have five stars, 934 have four stars, 1,770 have three stars, 723 have two stars and 133 have one star. The star ratings intend to convey the overall quality of nearly 4,000 hospitals in the U.S and are posted to the CMS' Hospital Compare website. The CMS used 64 measures that had already been posted to the Hospital Compare site. It grouped those measures into broader categories, then weighted them. Hospitals had to meet minimum reporting requirements in order to be eligible to receive a star rating. The new star ratings will be updated each quarter. For more, visit www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2016-Fact-sheets-items/2016-07-27.html.

    -back to top-
    Hospitals are hit with 88% of all ransomware attacks

    “Hospitals and health systems have more to lose than organizations in other sectors when it comes to hacks. Patient data sells for more money than any other kind of information on the black market. Adding insult to injury, a new report suggests that the healthcare industry is hit significantly harder by ransomware than in any other — 88 percent of attacks hit hospitals. Of the 88 percent of ransomware attacks that occurred in healthcare organizations, 94 percent were linked to a specific variant of software called Cryptowall, according to Solutionary's Security Engineering Research Team Quarterly Threat Report for Q2 2016…” To read the rest of this article, visit http://www.beckershospitalreview.com/healthcare-information-technology/hospitals-are-hit-with-88-of-all-ransomware-attacks.html.

    -back to top-
    Stock Watch
    Health Stocks

    Quotes last updated at 7/27/2016 5:30:32 PM EST

    Company Price Change Trends
    S&P 500 Index 2166.58 -2.60 Analyze
    NASDAQ Composite 5139.81 +29.76 Analyze
    ABBVIE INC 64.90 +0.45 Analyze
    AMERISOURCEBERGN 85.42 -0.29 Analyze
    ABBOTT LABS 43.67 +0.07 Analyze
    ALERE INC 31.47 -12.59 Analyze
    BAXTER INTL INC 48.32 +0.31 Analyze
    CR BARD INC 223.65 -7.82 Analyze
    BECTON DICKINSON 174.53 -0.50 Analyze
    BRISTOL MYERS SQ 76.47 +1.41 Analyze
    BOSTON SCIENTIFIC 23.66 -0.32 Analyze
    BOVIE MEDICAL CORP 1.90 +0.00 Analyze
    CARDINAL HEALTH 83.34 -0.30 Analyze
    CERNER CORP 61.95 -0.30 Analyze
    CLOROX 131.03 -2.86 Analyze
    CONMED CORP 48.20 -0.16 Analyze
    CEPHEID 33.10 +0.31 Analyze
    CRYOLIFE 14.05 +0.30 Analyze
    DANAHER 80.85 -0.27 Analyze
    DIVERSICARE HEALTHCARE SERVICES 8.865 +0.090 Analyze
    DYNACQ HEALTHCARE 0.006 +0.000 Analyze
    EXPRESS SCRIPTS 77.21 -1.28 Analyze
    GENERAL ELECTRIC COMPANY 31.28 -0.19 Analyze
    HCA 77.98 -1.68 Analyze
    HMS HOLDINGS 19.71 +0.47 Analyze
    HOLOGIC INC 37.20 +0.37 Analyze
    HILL-ROM HOLDINGS INC 52.31 +0.19 Analyze
    HENRY SCHEIN 179.01 -1.88 Analyze
    HEALTHSTREAM INC 24.27 -0.55 Analyze
    INTEGRA LIFESCIENCES HOLDINGS CORP 78.93 -0.31 Analyze
    ICU MEDICAL 115.73 +0.54 Analyze
    JOHNSON & JOHNSON 124.77 -0.38 Analyze
    MASIMO CORP 52.23 +0.17 Analyze
    MCKESSON CORP 196.92 +0.64 Analyze
    MEDASSETS 31.35 +0.00 Analyze
    MEDTRONIC INC 87.48 -0.77 Analyze
    MIMEDX GROUP INC 7.55 +0.02 Analyze
    3M COMPANY 178.27 +0.61 Analyze
    MERIT MEDICAL SYSTEMS 23.20 +1.08 Analyze
    MICROSOFT 56.19 -0.57 Analyze
    MYLAN LABS 46.93 +0.45 Analyze
    OMNICELL 36.22 +0.14 Analyze
    OWENS & MINOR 35.78 -0.10 Analyze
    PHILIPS 26.59 -0.15 Analyze
    PREMIER INC 32.19 -0.41 Analyze
    QUIDEL CORP 21.05 +0.20 Analyze
    SUPERIOR UNIFORM GROUP 16.81 -0.59 Analyze
    SMITH & NEPHEW 34.60 +0.08 Analyze
    STERIS CORP 70.28 +1.26 Analyze
    STANLEY BLACK & DECKER INC 122.36 -0.06 Analyze
    STRYKER CORP 114.83 -1.61 Analyze
    TELEFLEX MEDICAL 174.74 -2.81 Analyze
    THERMO FISHER SCI 158.90 +0.01 Analyze
    ZIMMER HOLDINGS 113.56 +0.00 Analyze
    -back to top-


    Copyright © , MDSI. All Rights Reserved.
    Privacy Policy